Episode 122 - November 22, 2024

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/33/e4/17/33e41777-1715-de84-12a9-769ac2340c6c/mza_15029894228347015687.jpg/600x600bb.jpg

Biotech Hangout

Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

112 episodes

20 hours ago

A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.

Life Sciences

Science

RSS

All content for Biotech Hangout is the property of Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/14285150/14285150-1617740863832-067e982347697.jpg

Episode 122 - November 22, 2024

Biotech Hangout

1 hour 7 seconds

3 months ago

Episode 122 - November 22, 2024

On this episode of Biotech Hangout, Eric Schmidt, Bruce Booth, Yaron Werber, Tim Opler and Mike Yee begin the show discussing the highlights from the Jefferies Healthcare Conference before taking a look at public investor sentiment this week. The discussion turns to Atlas Venture’s 2024 Year in Review and transitions into the emerging themes for 2025. The hosts also recap ACR Convergence including Amgen’s Phase 3 data as well as data from cell therapies for SLE, SSC, IMNM. The group also discuss lipid readouts from Eli Lilly, Silence Therapeutics and NewAmsterdam Pharma. Other topics covered include the Incyte and Escient deal collapse, Kura Oncology’s pact with Kyowa Kirin, and perspectives on Trump’s nomination of Dr. Mehmet Oz to lead the CMS. This episode aired on November 22, 2024.